Literature DB >> 25086511

A critical evaluation of worst case optimization methods for robust intensity-modulated proton therapy planning.

Albin Fredriksson1, Rasmus Bokrantz1.   

Abstract

PURPOSE: To critically evaluate and compare three worst case optimization methods that have been previously employed to generate intensity-modulated proton therapy treatment plans that are robust against systematic errors. The goal of the evaluation is to identify circumstances when the methods behave differently and to describe the mechanism behind the differences when they occur.
METHODS: The worst case methods optimize plans to perform as well as possible under the worst case scenario that can physically occur (composite worst case), the combination of the worst case scenarios for each objective constituent considered independently (objectivewise worst case), and the combination of the worst case scenarios for each voxel considered independently (voxelwise worst case). These three methods were assessed with respect to treatment planning for prostate under systematic setup uncertainty. An equivalence with probabilistic optimization was used to identify the scenarios that determine the outcome of the optimization.
RESULTS: If the conflict between target coverage and normal tissue sparing is small and no dose-volume histogram (DVH) constraints are present, then all three methods yield robust plans. Otherwise, they all have their shortcomings: Composite worst case led to unnecessarily low plan quality in boundary scenarios that were less difficult than the worst case ones. Objectivewise worst case generally led to nonrobust plans. Voxelwise worst case led to overly conservative plans with respect to DVH constraints, which resulted in excessive dose to normal tissue, and less sharp dose fall-off than the other two methods.
CONCLUSIONS: The three worst case methods have clearly different behaviors. These behaviors can be understood from which scenarios that are active in the optimization. No particular method is superior to the others under all circumstances: composite worst case is suitable if the conflicts are not very severe or there are DVH constraints whereas voxelwise worst case is advantageous if there are severe conflicts but no DVH constraints. The advantages of composite and voxelwise worst case outweigh those of objectivewise worst case.

Entities:  

Mesh:

Year:  2014        PMID: 25086511     DOI: 10.1118/1.4883837

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  20 in total

Review 1.  Robust Proton Treatment Planning: Physical and Biological Optimization.

Authors:  Jan Unkelbach; Harald Paganetti
Journal:  Semin Radiat Oncol       Date:  2018-04       Impact factor: 5.934

2.  Robust optimization for intensity-modulated proton therapy with soft spot sensitivity regularization.

Authors:  Wenbo Gu; Dan Ruan; Daniel O'Connor; Wei Zou; Lei Dong; Min-Yu Tsai; Xun Jia; Ke Sheng
Journal:  Med Phys       Date:  2019-01-21       Impact factor: 4.071

3.  Robust treatment planning with conditional value at risk chance constraints in intensity-modulated proton therapy.

Authors:  Yu An; Jianming Liang; Steven E Schild; Martin Bues; Wei Liu
Journal:  Med Phys       Date:  2017-01-03       Impact factor: 4.071

Review 4.  Empowering Intensity Modulated Proton Therapy Through Physics and Technology: An Overview.

Authors:  Radhe Mohan; Indra J Das; Clifton C Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-10-01       Impact factor: 7.038

5.  Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer.

Authors:  Wei Liu; Steven E Schild; Joe Y Chang; Zhongxing Liao; Yu-Hui Chang; Zhifei Wen; Jiajian Shen; Joshua B Stoker; Xiaoning Ding; Yanle Hu; Narayan Sahoo; Michael G Herman; Carlos Vargas; Sameer Keole; William Wong; Martin Bues
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-11-10       Impact factor: 7.038

6.  Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients.

Authors:  Heng Li; Xiaodong Zhang; Peter Park; Wei Liu; Joe Chang; Zhongxing Liao; Steve Frank; Yupeng Li; Falk Poenisch; Radhe Mohan; Michael Gillin; Ronald Zhu
Journal:  Radiother Oncol       Date:  2015-02-20       Impact factor: 6.280

Review 7.  Proton therapy - Present and future.

Authors:  Radhe Mohan; David Grosshans
Journal:  Adv Drug Deliv Rev       Date:  2016-12-03       Impact factor: 15.470

Review 8.  Applications of nanodosimetry in particle therapy planning and beyond.

Authors:  Antoni Rucinski; Anna Biernacka; Reinhard Schulte
Journal:  Phys Med Biol       Date:  2021-12-10       Impact factor: 3.609

9.  Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer.

Authors:  Chenbin Liu; Steven E Schild; Joe Y Chang; Zhongxing Liao; Shawn Korte; Jiajian Shen; Xiaoning Ding; Yanle Hu; Yixiu Kang; Sameer R Keole; Terence T Sio; William W Wong; Narayan Sahoo; Martin Bues; Wei Liu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-02-14       Impact factor: 7.038

10.  The role of image-guided intensity modulated proton therapy in glioma.

Authors:  David R Grosshans; Radhe Mohan; Vinai Gondi; Helen A Shih; Anita Mahajan; Paul D Brown
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.